The public healthcare AI market is emerging as a new growth engine. Medical AI specialist Coreline Soft, led by CEO Kim Jin-guk, announced on August 12th that it has officially signed a supply agreement with Seoul Boramae Medical Center’s Pulmonology Department to provide three AVIEW chest specialty products. This contract involves the introduction of various products—AVIEW COPD, AVIEW LCS Plus, and ILD—each designed for different purposes and formats, marking a notable case of an integrated model linking diagnosis, clinical practice, and research within Korea’s public healthcare AI adoption framework.
Amidst the active restructuring of the digital health policy environment led by the government and the expansion of healthcare AI reimbursement policies, Boramae Medical Center stands out as a leading public hospital under Seoul City, established by Seoul Metropolitan Government and operated under the supervision of Seoul National University Hospital. The hospital actively combines public service and research activities. The adoption of these AI solutions is expected to enhance the hospital’s multi-disease response capacity and contribute to the expansion of clinical research utilizing public healthcare data.
The three AVIEW chest products introduced by Coreline Soft are specialized for diagnosing chronic obstructive pulmonary disease (COPD), lung cancer and nodule detection (LCS), and interstitial lung disease (ILD). They feature automatic analysis based on low-dose chest CT scans and provide quantitative assessment functions. A representative from Coreline Soft stated, “We have maintained ongoing research collaborations with Boramae Medical Center, and after thorough verification of effectiveness in real clinical environments and data integration structures, we have decided to proceed with full-scale deployment. We also anticipate future joint academic achievements through diagnostics, multi-disciplinary research, and publications.”
2025.08.12
List